Kiyotsugu Iede

Dr. Kiyotsugu Iede

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
KIKiyotsugu Iede
Kiyotsugu Iede
ANAkimasa Nakao
Akimasa Nakao
KOKenji Oshima
Kenji Oshima
RSRyota Suzuki
Ryota Suzuki
HYHironori Yamada
Hironori Yamada
YKYasunori Kimura
Yasunori Kimura

28 August 2019 in Cancer Reports
Verified
Journal Article
Open access
PDF file
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
RKRyo Kato
Ryo Kato
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
STShusei Tominaga
Shusei Tominaga
Background: Second‐line (2 L) chemotherapy is important for improved survival. However, the efficacy of S‐1 after nab‐paclitaxel plus gemcitabine (AG) for advanced pancreatic cancer (APC) remains unclear.Aim: We retrospectively investigated the clinical impact of S‐1 after AG.Methods and results: From January 2015 to July 2018, 37 patients with APC underwent AG as first‐line chemotherapy at our institute. Of these patients, 14 (38%) underwent S‐1 as 2 L chemotherapy after AG (S‐1 group), five (14%) received another agent after AG, and 18 (49%) underwent no 2 L chemotherapy (best supportive care [BSC] group). The clinical features were retrospectively compared between the S‐1 and BSC groups. Prognostic factors for residual survival (RS) were analyzed using a Cox proportional hazards model. The induction rate of 2 L chemotherapy was 51%, and most patients received S‐1 monotherapy (74%). The disease control rate and progression‐free survival duration were 57.1% and 2.8 months, respectively. The median RS duration in the S‐1 and BSC groups was 5.2 and 2.4 months, respectively; this difference was statistically significant (hazard ratio, 0.33; P = .005). The median overall survival duration in the S‐1 and BSC groups was 12.3 and 5.0 months, respectively; this difference was also statistically significant (hazard ratio, 0.26; P = .001). The efficacy of S‐1 in 2L chemotherapy for RS was identified in the multivariate analysis, as was age (<65 vs ≥65 y) and the presence of liver metastasis.Conclusion: The antitumor activity of S‐1 was retained after AG, and the induction of S‐1 after AG might improve the prognosis of patients with APC.

23 September 2020 in Cancer Reports
Verified
Journal Article
Open access
PDF file
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
RKRyo Kato
Ryo Kato
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
STShusei Tominaga
Shusei Tominaga
Background: Second‐line (2L) chemotherapy after nab‐paclitaxel plus gemcitabine (AG) is important for improving the survival of patients with advanced pancreatic cancer (APC). However, many patients fail to receive 2L chemotherapy because of rapid disease progression. Therefore, early recognition of any ineffectiveness during AG might lead to an increased induction rate of 2L chemotherapy.Aim: We investigated the significance of treatment response at 8 weeks as a predictive factor for the induction of 2L chemotherapy after AG.Methods and results: From January 2015 to January 2019, 41 patients with APC underwent AG as first‐line chemotherapy at our institute. Thirty‐three patients were evaluated at 8 weeks. Sixteen patients (48%) underwent 2L chemotherapy and 17 (52%) underwent no 2L chemotherapy. Clinical features and treatment response at 8 weeks were, retrospectively, compared among patients. Predictive factors for the induction of 2L chemotherapy were analyzed. Patients with an objective response by 8 weeks received 2L chemotherapy more frequently (P = .026). Decreased CA19‐9 (<50%) at 8 weeks was identified as an independent negative predictive factor for the induction of 2L chemotherapy.Conclusions: Decreased CA19‐9 (<50%) at 8 weeks may indicate the ineffectiveness of AG and signify that a move to 2L chemotherapy may be required without delay.

22 July 2022 in Medicine
Verified
Journal Article
Open access
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
SNShinsuke Nakashima
Shinsuke Nakashima
STShusei Tominaga
Shusei Tominaga
Although the antitumor effects of antihypertensive drugs for patients with advanced pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous studies suggest that hypertensive (HT) patients with APC are significantly older than non-HT patients with APC, and that other major baseline differences in patient characteristics which may affect prognosis exist between HT and non-HT patients. It is also possible that antihypertensive drugs lack antitumor activity. Therefore, we herein retrospectively investigated the baseline differences between HT and non-HT patients with APC. From January 2015 to April 2020, 56 patients with APC received nab-paclitaxel plus gemcitabine as first-line chemotherapy at Higashiosaka City Medical Center (Higashiosaka, Japan). Of these 56 patients, 30 were diagnosed with hypertension (HT group); the remaining 26 did not have hypertension (non-HT group). Differences between the two groups were compared and prognostic factors were evaluated. Patients in the HT group had significantly less sarcopenia, a significantly larger body mass index, were significantly older, and significantly more likely to have a regular doctor and primary site in the body and tail of the pancreas than those in the non-HT group. Although no significant difference was found in the treatment response, patients in the HT group were significantly more likely to move to second-line chemotherapy than those in the non-HT group. Survival curves showed that median overall survival (OS) in the HT group was significantly longer (10.5 months) than in the non-HT group (6.8 months, P = .04). Multivariate analysis did not identify the use of antihypertensive drugs as an independent prognostic factor of OS. We identified key baseline differences in the characteristics of APC patients with and without HT, suggesting that major selection bias could occur when investigating the efficacy of antihypertensive drugs in all populations. Therefore, it is possible that antihypertensive drugs lack antitumor activity. To determine the true efficacy of antihypertensive drugs for APC, HT, and non-HT patients in another population should be investigated, or a prospective, randomized, controlled trial conducted that is stratified by HT or non-HT status.

1 August 2020 in Pancreas
Verified
Journal Article
Closed access
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
RKRyo Kato
Ryo Kato
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
STShusei Tominaga
Shusei Tominaga

1 January 2020 in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
Verified
Journal Article
Open access
PDF file
NSNaoko Sekiguchi
Naoko Sekiguchi
MIMasakazu Ikenaga
Masakazu Ikenaga
MIMariko Ikegami
Mariko Ikegami
KIKiyotsugu Iede
Kiyotsugu Iede
MUMasami Ueda
Masami Ueda
TYTerumasa Yamada
Terumasa Yamada
症例は68歳,男性.自慰目的で肛門から瓜を挿入し,排出困難となり当院を受診した.腹部単純CTで16×7cm大の瓜を直腸RS付近に認め,腸管穿孔所見は認めなかった.摘出の際に腸管損傷の可能性を考え,全身麻酔下での摘出を試みた.全身麻酔下,砕石位で手術を開始した.肛門括約筋の弛緩は得られたが肛門内に異物は確認できず,下腹部圧排で瓜の頂部をわずかに確認できた.ミュゾー鉗子で把持を試みるも困難であり,子宮筋腫用のミオームボーラーを瓜に挿入し,下腹部の圧排と牽引で摘出を試みた.しかし,瓜は脆弱でミオームボーラー挿入部が砕けるため,別角度からもう1本挿入することで力を分散し脆弱性を補うことで腹部圧迫を併用し摘出に成功した.直腸異物は多種多様の異物が報告されており,摘出方法の工夫が必要である.今回直腸異物(瓜)に対して,異物の大きさと摘出器具の特徴を術前に綿密に確認することで安全に摘出しえた症例を経験した.